<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The <z:hpo ids='HP_0002511'>Alzheimer Disease</z:hpo> Assessment Scale (ADAS) is a scale specifically structured for the assessment of the <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> and <z:e sem="disease" ids="C0004930" disease_type="Mental or Behavioral Dysfunction" abbrv="">behavioral disorder</z:e> seen in <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> (AD) patients </plain></SENT>
<SENT sid="1" pm="."><plain>AIM OF THE STUDY: The validation of ADAS in the Greek population </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIAL: One hundred and thirty-one subjects took part in the current study </plain></SENT>
<SENT sid="3" pm="."><plain>Fifty of them were nondemented subjects (35 <z:mpath ids='MPATH_458'>normal</z:mpath> subjects and 15 suffering from age-associated <z:hpo ids='HP_0002354'>memory impairment</z:hpo>) and 81 demented patients (68 AD patients and 13 vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, VD, patients) </plain></SENT>
<SENT sid="4" pm="."><plain>METHOD: Diagnosis was made according to <z:chebi fb="4" ids="38624">DSM</z:chebi>-IV and NINCDS-ADRDA criteria </plain></SENT>
<SENT sid="5" pm="."><plain>Hachinski <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> Scale was used to help to differentiate between AD and VD patients </plain></SENT>
<SENT sid="6" pm="."><plain>Geriatric <z:hpo ids='HP_0000716'>Depression</z:hpo> Scale was used to quantify depressive symptomatology </plain></SENT>
<SENT sid="7" pm="."><plain>MMSE and CAMCOG were used to assess the cognitive functioning of <z:hpo ids='HP_0000001'>all</z:hpo> subjects and FRSSD for the assessment of daily functioning </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects underwent a complete laboratory and biochemical testing, according to the protocol proposed in CAMDEX </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> patients underwent brain CT </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: ADAS-Cog discriminates perfectly AD patients and nondemented subjects at the score level of 13/14 and/or 14/15 </plain></SENT>
<SENT sid="11" pm="."><plain>Principal components analysis, using only AD patients, revealed 4 factors: cognitive, <z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e>, depressive, and 'severe <z:hpo ids='HP_0002186'>apraxia</z:hpo>' factors </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: ADAS is suitable for use in the discrimination between AD patients and nondemented subjects </plain></SENT>
<SENT sid="13" pm="."><plain>It is also suitable for a more comprehensive assessment of the clinical symptomatology of AD patients, and for the evaluation of new therapeutic methods for AD, as well </plain></SENT>
</text></document>